Dianthus Therapeutics, Inc. /DE/
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.0M | $6.2M | $2.8M | — | — |
| Operating income | -$177.9M | -$101.9M | -$48.2M | -$29.7M | -$74.7M |
| Operating expenses | $180.0M | $108.1M | $51.0M | $36.1M | $74.7M |
| Cash from operations | -$129.1M | -$78.2M | -$36.9M | -$29.1M | -$59.5M |
| Capital expenditure | — | — | — | $314,000 | $1.3M |
| Free cash flow | — | — | — | -$29.4M | -$60.8M |
| Impairments | — | — | — | $0 | $0 |
| Total assets | $530.9M | $374.0M | $179.4M | $83.1M | $189.9M |
| Total liabilities | $37.5M | $21.5M | $10.5M | $9.5M | $17.3M |
Shares outstanding 54.7M · Free float 89.3%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.